GlassScriptPhysician profile
Aditi Saha
NPI 1487132205
$1,021.29
in general payments reported to CMS, 2019-2025
13 companies · $677 in 2025
The $677 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.29 · 2022: $84.96 · 2023: $116 · 2024: $107 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811 · Travel and Lodging: $89.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.57 |
| Travel and Lodging | $89.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $169.24 | 2025 | Brukinsa |
| Sobi, INC | $167.98 | 2025 | |
| Recordati_rare_diseases_inc. | $129.96 | 2024-2025 | Sylvant |
| Genzyme Corporation | $115.69 | 2023 | |
| Incyte Corporation | $109.06 | 2025 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $108.92 | 2025 | Breyanzi |
| Lilly USA, LLC | $84.96 | 2022 | |
| Celgene Corporation | $37.56 | 2025 | |
| Medtronic, INC. | $36.29 | 2021 | |
| Tempus Ai, INC | $22.40 | 2025 | Xt Cdx |
| Adc Therapeutics America, INC. | $20.12 | 2025 | |
| Beigene USA, INC. | $19.11 | 2025 | Brukinsa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditi Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.